Biotalys Hits Milestone for First Commercial Biofungicide Product

Biotalys, an ag tech company developing protein-based biocontrol solutions for sustainable crop protection, has announced the successful completion of a pilot production campaign for Evoca NG, the company’s first AGROBODY commercial biofungicide product candidate.

Conducted in partnership with 21st.BIO, a leading precision fermentation technology provider, the campaign successfully demonstrated the consistency and scalability of Biotalys’ manufacturing process for EVOCA NG across five consecutive production batches. This important manufacturing achievement provides critical material and process validation data to support product registrations activities, while further advancing the company’s readiness for future commercial-scale production and market launch.

EVOCA NG is developed on Biotalys’ proprietary AGROBODY technology platform to help fruit and vegetable growers effectively control the key fungal diseases Botrytis (grey mold) and powdery mildew. Expected to be Biotalys’ first commercial biofungicide, EVOCA NG is planned for registration in both the U.S. and E.U. in 2029.

EVOCA NG has the same bioactive ingredient as EVOCA, the first-generation product that received EPA approval in the U.S. in Dec. 2025 and state approval in Florida and California in 2026.

For more information, continue reading at biotalys.com.